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In total, 274 participants are competing in NSC2. These participants include life sci-
ences industry players, serial entrepreneurs, angel investors, broadly trained scientists 
and engineers, experienced attorneys, and budding entrepreneurs with complemen-
tary backgrounds. Teams applied to the challenge through a Letter of Intent where they 
answered questions about their experience, role on the team and why they want to enter 
the challenge (Fig. 1). CAI evaluated these teams on more than forty criteria, which we 
developed through an analysis of successful startups. Each team has at least two cur-
rently enrolled students and one seasoned entrepreneur with more than 3  years in a 
startup. Twenty teams are based in the United States, three are based in China, two are 
based in Canada, two are based in England, and one is based in Brazil. Of the US teams, 
nine are based in the Maryland-Washington, DC-Virginia area.
Abstract 
On March 4th, 2016, Springer’s Cancer Nanotechnology office promoted the launch of 
the Nanotechnology Startup Challenge in Cancer (NSC2). This innovation-development 
model is a partnership among our company, the Center for Advancing Innovation 
(CAI), MedImmune, the global biologics arm of AstraZeneca, and multiple institutes 
at the National Institutes of Health (NIH). NSC2 “crowdsources” talent from around the 
world to launch startups with near-term, commercially viable cancer nanotechnology 
inventions, which were developed by the National Cancer Institute (NCI), the National 
Heart, Lung and Blood Institute (NHLBI), and the National Institute of Biomedical 
Imaging and Bioengineering (NIBIB). Crowdsourcing is a process in which one uses the 
internet to engage a large group of people in an activity, such as NSC2. For this initia-
tive, CAI engaged universities, industry professionals, foundations, investors, relevant 
media outlets, seasoned entrepreneurs, and life sciences membership organizations to 
request that they participate in the challenge. From this outreach, fifty-six key thought 
leaders have enrolled in NSC2 as judges, mentors, and/or advisors to challenge teams 
(http://www.nscsquared.org/judges.html). Along with crowdsourcing talent to bolt 
startups around NIH inventions, NSC2 will also catalyze the launch of companies around 
“third-party” cancer nanotechnology inventions, which were conceived and developed 
outside of the NIH. Twenty-eight robust teams were accepted to the challenge on 
March 14th, 2016.
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Through NSC2, twenty-four teams are competing to license eight NIH inventions, 
whereas four teams submitted their own inventions with strong commercialization 
potential. Of the eight NIH inventions, three are drug candidates, three are diagnostics, 
and two have the potential of being therapeutics and/or diagnostics.
What outcomes do we hope to achieve through NSC2? This challenge, like our prior 
ones, is not simply a business plan competition. Our objective is to launch up to fifteen 
startups, which will commercialize the promising inventions in this challenge. The sheer 
impact that can be made through the NSC2 program is meaningful. First, nanotechnol-
ogy itself is disruptive and could allow innovators to fine-tune existing cancer therapies 
without a need to develop new bioactive compounds. We hypothesize that nanotechnol-
ogy will significantly decrease cancer-driven mortality rates, reduce the invasiveness of 
cancer diagnostics, and allow current therapeutics to target the cancer cells more pre-
cisely, thereby eliminating harmful side effects.
While making a timely and positive impact on human health, we also hope to create 
“gazelles” and potentially even “unicorns” or “dragons” from NSC2. Gazelles are com-
panies that double revenue and jobs every 4  years. Unicorns are companies that earn 
a billion-dollar valuation within 5 years of being launched and 1.28 % of new startups 
have a chance of being a unicorn.  There are only 229 of unicorns; and, only 8 of them 
are life sciences related. Dragons, on the other hand, may not be valued at over $1 bil-
lion; yet, dragons are extremely profitable, returning all of the capital issued out of the 
fund—a “fund-maker.” In the startup world, these creatures are not mythical. However, 
they are rare. Dragons are four times rarer than unicorns, and only 27 % of unicorns are 
fund-makers. In addition to launching promising startups, we also will train hundreds of 
university students, post-docs, and others who have entered the challenge on the “busi-
ness of science”. So far, CAI’s accelerator has trained 1000+ people through 40 classes, 
Fig. 1 Word cloud map created by Rosemarie Truman based on NSC2 entrants answers to Letter of Intent 
questions upon entry into the challenge
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homework and hands-on experiential learning exercises that focus on how to develop 
business plans, create financial models, perform live pitches and raise money.
To create near-mythical startups, NSC2 teams will pursue a diversity of cancer nano-
technology inventions. The three exclusively therapeutic NIH inventions are photoac-
tivatable liposomes for targeted drug delivery (Yavlovich et  al. 2009, 2011; Puri et  al. 
2011), nucleic acid nanocubes for triggering RNA interference (Afonin et  al. 2010, 
2014a), and carbohydrate-encapsulated gold nanoparticles for inhibiting metastasis 
(Svarovsky and Barchi 2003; Brinãs et al. 2012). Seven, one and two teams will pursue 
these therapeutics, respectively. The three exclusively diagnostic NIH inventions are a 
carbon nanotube transistor-based microarray binding sensor (Subramanian et al. 2012), 
a DNA-tethered bead immunoassay (Silver et al. 2015), and an enzyme-catalyzed gold 
nanoparticle-based colorimetric assay (Liu et al. 2014). Six, one, and two teams will pur-
sue these diagnostics, respectively. The remaining inventions are nucleic acid nanopar-
ticles (Afonin et al. 2014b), which have been shown to induce RNA interference (Afonin 
et al. 2015), and polymer-coated gold nanorod assemblies for targeted, imaging-guided 
photothermal therapy (Rong et al. 2015; Song et al. 2015). Two and three teams will pur-
sue these multifunctional inventions, respectively. One may find overviews of these eight 
inventions, offered through NSC2, at http://www.nscsquared.org/inventions.html.
We interviewed an NSC2 team leader, Elizabeth Cho-Fertikh, Ph.D. of Washington, 
DC, about her participation in this challenge. She noted, “I entered the challenge hav-
ing been on the research and investor sides for many years, but never as an entrepre-
neur. The greatest value I have obtained so far from NSC2 is developing a venture with so 
much support in a structured and well-organized manner from the sponsors, obtaining 
pearls of wisdom throughout the process.” Dr. Cho-Fertikh’s team will attempt to com-
mercialize a third-party peptide-based approach to target alternatively activated M2 
macrophages (Cieslewicz et al. 2013; Ngambenjawong et al. 2016).
Phase 1 of NSC2 ended on April 17th, 2016. Each team submitted a two-minute “eleva-
tor speech”, which summarizes their chosen invention and potential startup, for public 
access and voting. Public voting was held between April 18th and April 22nd. The eleva-
tor speeches can be viewed at https://www.youtube.com/playlist?list=PLvu6n-GsGF-
sYNp-TFHeYOrB_bpaYYrjHM. Although public voting has closed, we would appreciate 
additional comments, likes, and shares of these elevator speeches. Feedback from the 
readers of Cancer Nanotechnology will be valuable to NSC2 participants and would serve 
to further the educational goals of this NIH-supported initiative. CAI announced final-
ists from Phase 1 on April 25th. After moving on to Phase 2, teams will write ten-page 
business plans, create robust financial models, and pitch to our panel of judges. The 
NSC2 teams may continue to add teammates through the challenge. To join an existing 
team, visit http://www.nscsquared.org/find-a-team–member.html.
You can find out more about each of the inventions from the references list below. We 
are most grateful to the Cancer Nanotechnology editorial team for helping to promote 
NSC2. Stay tuned for a Special Collection of articles, related to the inventions in NSC2 
and authored by the teams.
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